Apremilast

CAT: 0804-HY-12085-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-12085-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM[1].
CAS Number
[608141-41-9]
Product Name Alternative
CC-10004
UNSPSC
12352005
Hazard Statement
H302, H312, H332, H361, H372
Target
Apoptosis; Phosphodiesterase (PDE) ; TNF Receptor
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Apremilast.html
Purity
99.91
Solubility
DMSO : 44 mg/mL (ultrasonic)
Smiles
CC(NC1=CC=CC(C(N2[C@@H](C3=CC=C(OC)C(OCC)=C3)CS(=O)(C)=O)=O)=C1C2=O)=O
Molecular Formula
C22H24N2O7S
Molecular Weight
460.50
Precautions
H302, H312, H332, H361, H372
References & Citations
[1]Perez-Aso M, et al. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther. 2015 Sep 15;17:249.|[2]Chen LG, et al. Determination of Apremilast in Rat Plasma by UPLC-MS-MS and Its Application to a Pharmacokinetic Study. J Chromatogr Sci. 2016 Sep;54 (8) :1336-40.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
PDE4; TNFRSF5/CD40

Related Products

CatalogName